Research statistics

Thymosin Alpha-1 research: publications and trials

What has been published on Thymosin Alpha-1: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Thymosin Alpha-1 works or is safe. For what it is and what the studies found, see the Thymosin Alpha-1 profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

782

Since 1977

Publications in 2026 so far

20

Through November 15, 2026

Human clinical research

27.3%

208 of 762 classified

Registered clinical trials

60

ClinicalTrials.gov

Randomized controlled trials

73

Publications reporting an RCT in people

Systematic reviews and meta-analyses

23

Preclinical studies

54.1%

258 animal · 148 in vitro · 6 computational

Records that only mention it

182

Not counted above

Status in the library: Research only. Groups: Thymic peptides. 20 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.
  • The body makes this molecule itself, so much of its literature is physiology rather than research on it as a compound.

Publications by year

Thymosin Alpha-1 publications by year and evidence

1977, Preclinical (animal, in vitro, computational): 1 of 11978, Preclinical (animal, in vitro, computational): 1 of 11979, Preclinical (animal, in vitro, computational): 3 of 51979, Other and not yet classified: 2 of 51980, Preclinical (animal, in vitro, computational): 3 of 61980, Other and not yet classified: 3 of 61981, Human clinical research: 1 of 101981, Preclinical (animal, in vitro, computational): 6 of 101981, Reviews and meta-analyses: 1 of 101981, Other and not yet classified: 2 of 101982, Preclinical (animal, in vitro, computational): 8 of 101982, Other and not yet classified: 2 of 101983, Human clinical research: 3 of 261983, Preclinical (animal, in vitro, computational): 18 of 261983, Reviews and meta-analyses: 1 of 261983, Other and not yet classified: 4 of 261984, Human clinical research: 6 of 231984, Preclinical (animal, in vitro, computational): 15 of 231984, Reviews and meta-analyses: 1 of 231984, Other and not yet classified: 1 of 231985, Human clinical research: 5 of 281985, Preclinical (animal, in vitro, computational): 18 of 281985, Reviews and meta-analyses: 3 of 281985, Other and not yet classified: 2 of 281986, Human clinical research: 3 of 141986, Preclinical (animal, in vitro, computational): 11 of 141987, Human clinical research: 4 of 241987, Preclinical (animal, in vitro, computational): 16 of 241987, Reviews and meta-analyses: 1 of 241987, Other and not yet classified: 3 of 241988, Human clinical research: 3 of 191988, Preclinical (animal, in vitro, computational): 16 of 191989, Human clinical research: 5 of 221989, Preclinical (animal, in vitro, computational): 16 of 221989, Reviews and meta-analyses: 1 of 221990, Human clinical research: 1 of 131990, Preclinical (animal, in vitro, computational): 12 of 131991, Human clinical research: 3 of 121991, Preclinical (animal, in vitro, computational): 9 of 121992, Human clinical research: 1 of 191992, Preclinical (animal, in vitro, computational): 16 of 191992, Reviews and meta-analyses: 1 of 191992, Other and not yet classified: 1 of 191993, Human clinical research: 3 of 91993, Preclinical (animal, in vitro, computational): 6 of 91994, Human clinical research: 2 of 111994, Preclinical (animal, in vitro, computational): 6 of 111994, Reviews and meta-analyses: 2 of 111994, Other and not yet classified: 1 of 111995, Human clinical research: 3 of 121995, Preclinical (animal, in vitro, computational): 8 of 121995, Reviews and meta-analyses: 1 of 121996, Human clinical research: 9 of 201996, Preclinical (animal, in vitro, computational): 9 of 201996, Other and not yet classified: 2 of 201997, Human clinical research: 1 of 111997, Preclinical (animal, in vitro, computational): 7 of 111997, Reviews and meta-analyses: 1 of 111997, Other and not yet classified: 2 of 111998, Human clinical research: 5 of 121998, Preclinical (animal, in vitro, computational): 6 of 121998, Reviews and meta-analyses: 1 of 121999, Human clinical research: 2 of 101999, Preclinical (animal, in vitro, computational): 5 of 101999, Reviews and meta-analyses: 2 of 101999, Other and not yet classified: 1 of 102000, Human clinical research: 6 of 192000, Preclinical (animal, in vitro, computational): 7 of 192000, Reviews and meta-analyses: 5 of 192000, Other and not yet classified: 1 of 192001, Human clinical research: 3 of 82001, Preclinical (animal, in vitro, computational): 4 of 82001, Reviews and meta-analyses: 1 of 82002, Human clinical research: 4 of 142002, Preclinical (animal, in vitro, computational): 6 of 142002, Reviews and meta-analyses: 2 of 142002, Other and not yet classified: 2 of 142003, Human clinical research: 4 of 122003, Preclinical (animal, in vitro, computational): 4 of 122003, Reviews and meta-analyses: 4 of 122004, Human clinical research: 9 of 212004, Preclinical (animal, in vitro, computational): 7 of 212004, Reviews and meta-analyses: 4 of 212004, Other and not yet classified: 1 of 212005, Human clinical research: 5 of 212005, Preclinical (animal, in vitro, computational): 14 of 212005, Reviews and meta-analyses: 2 of 212006, Human clinical research: 7 of 132006, Preclinical (animal, in vitro, computational): 5 of 132006, Other and not yet classified: 1 of 132007, Human clinical research: 9 of 282007, Preclinical (animal, in vitro, computational): 13 of 282007, Reviews and meta-analyses: 4 of 282007, Other and not yet classified: 2 of 282008, Human clinical research: 6 of 122008, Preclinical (animal, in vitro, computational): 6 of 122009, Human clinical research: 7 of 222009, Preclinical (animal, in vitro, computational): 8 of 222009, Reviews and meta-analyses: 6 of 222009, Other and not yet classified: 1 of 222010, Human clinical research: 4 of 202010, Preclinical (animal, in vitro, computational): 5 of 202010, Reviews and meta-analyses: 10 of 202010, Other and not yet classified: 1 of 202011, Human clinical research: 5 of 162011, Preclinical (animal, in vitro, computational): 8 of 162011, Reviews and meta-analyses: 3 of 162012, Human clinical research: 3 of 162012, Preclinical (animal, in vitro, computational): 6 of 162012, Reviews and meta-analyses: 7 of 162013, Human clinical research: 2 of 92013, Preclinical (animal, in vitro, computational): 6 of 92013, Reviews and meta-analyses: 1 of 92014, Human clinical research: 1 of 52014, Preclinical (animal, in vitro, computational): 3 of 52014, Reviews and meta-analyses: 1 of 52015, Human clinical research: 5 of 272015, Preclinical (animal, in vitro, computational): 17 of 272015, Reviews and meta-analyses: 3 of 272015, Other and not yet classified: 2 of 272016, Human clinical research: 4 of 152016, Preclinical (animal, in vitro, computational): 4 of 152016, Reviews and meta-analyses: 7 of 152017, Human clinical research: 2 of 132017, Preclinical (animal, in vitro, computational): 7 of 132017, Reviews and meta-analyses: 2 of 132017, Other and not yet classified: 2 of 132018, Human clinical research: 4 of 262018, Preclinical (animal, in vitro, computational): 12 of 262018, Reviews and meta-analyses: 7 of 262018, Other and not yet classified: 3 of 262019, Human clinical research: 3 of 142019, Preclinical (animal, in vitro, computational): 9 of 142019, Reviews and meta-analyses: 2 of 142020, Human clinical research: 7 of 232020, Preclinical (animal, in vitro, computational): 10 of 232020, Reviews and meta-analyses: 4 of 232020, Other and not yet classified: 2 of 232021, Human clinical research: 6 of 142021, Preclinical (animal, in vitro, computational): 4 of 142021, Reviews and meta-analyses: 4 of 142022, Human clinical research: 11 of 182022, Preclinical (animal, in vitro, computational): 5 of 182022, Reviews and meta-analyses: 1 of 182022, Other and not yet classified: 1 of 182023, Human clinical research: 9 of 262023, Preclinical (animal, in vitro, computational): 11 of 262023, Reviews and meta-analyses: 6 of 262024, Human clinical research: 6 of 122024, Preclinical (animal, in vitro, computational): 3 of 122024, Reviews and meta-analyses: 3 of 122025, Human clinical research: 10 of 202025, Preclinical (animal, in vitro, computational): 5 of 202025, Reviews and meta-analyses: 4 of 202025, Other and not yet classified: 1 of 202026 (to date), Human clinical research: 6 of 202026 (to date), Preclinical (animal, in vitro, computational): 7 of 202026 (to date), Reviews and meta-analyses: 6 of 202026 (to date), Other and not yet classified: 1 of 20Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified0102030197719871997200720172026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
197701001
197801001
197903025
198003036
1981161210
1982080210
19833181426
19846151123
19855183228
19863110014
19874161324
19883160019
19895161022
19901120013
1991390012
19921161119
199336009
1994262111
1995381012
1996990220
1997171211
1998561012
1999252110
2000675119
200134108
2002462214
2003444012
2004974121
20055142021
2006750113
20079134228
2008660012
2009786122
20104510120
2011583016
2012367016
201326109
201413105
20155173227
2016447015
2017272213
20184127326
2019392014
20207104223
2021644014
20221151118
20239116026
2024633012
20251054120
2026 (to date)676120

Study types

Animal study258
In vitro study148
Review92
Randomized controlled trial73
Observational human study67
Other clinical trial52
Editorial, letter or other27
Meta-analysis22
Not yet classified20
Case report16
Computational study6
Systematic review1

Research areas

From MeSH major topics. A paper can be in several areas.

Immune system396
Antimicrobial and infectious disease240
Oncology195
Gastrointestinal152
Endocrinology34
Reproductive and sexual health34
Longevity and aging28
Neurological and mental health26
Dermatology23
Tissue repair17
Cardiovascular14
Metabolic health11

Registered clinical trials

6 of 17 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 23 · Unknown status: 16 · Recruiting: 8 · Not yet recruiting: 5 · Withdrawn: 4 · Active, not recruiting: 2 · Enrolling by invitation: 1 · Terminated: 1
Early phase 1: 1 · Phase not applicable: 11 · Phase 1: 2 · Phase 1 / Phase 2: 3 · Phase 2: 25 · Phase 2 / Phase 3: 1 · Phase 3: 7 · Phase 4: 10

TrialStatusPhaseStartedResults
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic DissectionNCT07382375 · 300 enrolledNot yet recruitingPhase not applicable2027-12—
Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant TreatmentNCT07884201 · 572 enrolledNot yet recruitingPhase 22026-11—
Thymalfasin for Immune Recovery in Adults With SepsisNCT07866118 · 60 enrolledRecruitingPhase not applicable2026-10—
Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal CancerNCT07780721 · 31 enrolledNot yet recruitingPhase 22026-08—
Thymosin Alpha 1 and IgM Levels in SepsisNCT07922954 · 36 enrolledActive, not recruitingPhase 42026-02—
Thymosin-α1 for Recurrent Implantation FailureNCT07675980 · 136 enrolledRecruitingPhase 2, Phase 32026-02—
Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)NCT06966687 · 200 enrolledEnrolling by invitationPhase not applicable2025-04—
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"NCT06829355 · 52 enrolledRecruitingPhase 22025-02—
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 VaccineNCT06821100 · 75 enrolledRecruitingPhase 12024-12—
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLCNCT06607926 · 40 enrolledUnknown statusPhase not applicable2024-10—
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPCNCT06573398 · 20 enrolledNot yet recruitingPhase 22024-09—
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological TumorsNCT06584006 · 50 enrolledRecruitingPhase 22024-09—
Immuno-effect of Tα1 for Stage I NSCLCNCT06598839 · 40 enrolledUnknown statusPhase not applicable2024-06—
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction AdenocarcinomaNCT06461910 · 30 enrolledRecruitingPhase 22024-06—
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal CancerNCT06056804 · 20 enrolledActive, not recruitingPhase 22024-01—
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal CancerNCT06024356 · 47 enrolledCompletedPhase not applicable2023-09—
Thymosin Alpha-1 for irAE Secondary to ICIsNCT06178146 · 40 enrolledUnknown statusPhase 42023-09—
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLCNCT06139419 · 114 enrolledCompletedPhase 22023-07—
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaNCT07644897 · 55 enrolledRecruitingPhase 22023-05—
Thymalfasin-based PRaG Mode for Advanced Refractory Solid TumorsNCT05790447 · 60 enrolledUnknown statusPhase 22023-04—
Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)NCT05339529 · 600 enrolledCompletedPhase not applicable2022-07—
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary BypassNCT05487469 · 200 enrolledUnknown statusPhase not applicable2022-07—
Zadaxin and HIV-positive Patients With Immune Reconstitution DisorderNCT04963712 · 20 enrolledCompletedEarly phase 12021-09—
Long-term Prognosis of Patients With Sepsis After ImmunotherapyNCT04901104 · 900 enrolledNot yet recruitingPhase not applicable2021-07—
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal CancerNCT05086614 · 2,500 enrolledRecruitingPhase 32021-04—
Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis PatientsNCT04428008 · 189 enrolledCompletedPhase 22021-01Posted
Immunotherapy for Elderly Patients With Chronic Osteoporotic PainNCT04524169 · 100 enrolledUnknown statusPhase 42020-11—
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 InfectionNCT04487444 · 56 enrolledTerminatedPhase 22020-09—
Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical StaffNCT04320238 · 2,944 enrolledUnknown statusPhase 32020-01—
Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung CancerNCT03659578 · 69 enrolledCompletedPhase 22018-08—
Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing PancreatitisNCT02473406 · 508 enrolledCompletedPhase 42018-03—
Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced PatientsNCT03448744 · 240 enrolledUnknown statusPhase 42017-10—
The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLFNCT03082885 · 120 enrolledCompletedPhase not applicable2017-04—
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyNCT02976740 · 48 enrolledUnknown statusPhase 22016-11—
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care TherapyNCT02906163 · 188 enrolledUnknown statusPhase 1, Phase 22016-10—
The Efficacy and Safety of Ta1 for SepsisNCT02867267 · 1,106 enrolledCompletedPhase 32016-09—
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild TypeNCT02906150 · 140 enrolledUnknown statusPhase 22016-09—
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI TherapyNCT02787447 · 46 enrolledUnknown statusPhase 22016-05—
Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for SepsisNCT02883595 · 20 enrolledCompletedPhase 42016-03—
Abscopal Effect for Metastatic Non-small Cell Lung Cancer.NCT02542930WithdrawnPhase 22016-01—
SBRT Combined With Thymalfasin for Metastatic Esophageal CancerNCT02545751 · 29 enrolledUnknown statusPhase 22016-01—
Abscopal Effect for Metastatic Colorectal CancerNCT02535988WithdrawnPhase 22015-09—
Abscopal Effect for Metastatic Small Cell Lung CancerNCT02542137WithdrawnPhase 22015-09—
Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative ResectionNCT02281266 · 360 enrolledUnknown statusPhase 42015-01—
Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis BNCT02366247 · 463 enrolledUnknown statusPhase 32013-08—
Optimized Treatment and Regression of HBV-induced Early CirrhosisNCT01938820 · 82 enrolledCompletedPhase 42013-06—
Optimized Treatment and Regression of HBV-induced Compensated Liver CirrhosisNCT01943617 · 606 enrolledCompletedPhase 42013-06—
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected PatientsNCT02646189 · 12 enrolledCompletedPhase 1, Phase 22011-08—
Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis BNCT02366208 · 116 enrolledCompletedPhase 22011-05—
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza VaccineNCT01031966 · 120 enrolledCompletedPhase 22009-11—

The 50 most recently started of 60 trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Efficacy and safety of thymosin α1 combined with chemotherapy for gastric cancer: a systematic review and meta-analysis of randomized controlled trials.

    Frontiers in immunology · September 18, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42827862 · DOI 10.3389/fimmu.2026.1884797 · Reviews and meta-analyses

  2. Thymosin-ɑ1 for people with chronic hepatitis B.

    The Cochrane database of systematic reviews · September 9, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42713852 · DOI 10.1002/14651858.cd014610.pub2 · Reviews and meta-analyses

  3. Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.

    Frontiers in cellular and infection microbiology · September 3, 2025 · Meta-analysis · cited 3 times · open access

    PMID 40969554 · DOI 10.3389/fcimb.2025.1673959 · Reviews and meta-analyses

  4. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.

    Frontiers in immunology · June 17, 2025 · Meta-analysis · cited 4 times · open access

    PMID 40599771 · DOI 10.3389/fimmu.2025.1571456 · Reviews and meta-analyses

  5. The Effect of Ulinastatin on Sepsis Outcomes: An Umbrella Review of Meta-Analysis.

    Clinical therapeutics · March 6, 2025 · Meta-analysis · cited 1 times

    PMID 40055068 · DOI 10.1016/j.clinthera.2025.01.013 · Reviews and meta-analyses

  6. Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP · December 1, 2024 · Meta-analysis · cited 2 times · open access

    PMID 39648386 · DOI 10.29271/jcpsp.2024.12.1497 · Reviews and meta-analyses

  7. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.

    Inflammopharmacology · October 16, 2023 · Meta-analysis · cited 4 times

    PMID 37845598 · DOI 10.1007/s10787-023-01354-2 · Reviews and meta-analyses

  8. Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.

    International immunopharmacology · December 13, 2022 · Meta-analysis · cited 9 times · open access

    PMID 36527881 · DOI 10.1016/j.intimp.2022.109584 · Reviews and meta-analyses

  9. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.

    BMC gastroenterology · October 19, 2020 · Meta-analysis · cited 8 times · open access

    PMID 33076834 · DOI 10.1186/s12876-020-01477-8 · Reviews and meta-analyses

  10. Interventions for treating traumatised permanent front teeth: avulsed (knocked out) and replanted.

    The Cochrane database of systematic reviews · February 5, 2019 · Meta-analysis · cited 14 times

    PMID 30720860 · DOI 10.1002/14651858.cd006542.pub3 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Immunologic abnormalities in the acquired immunodeficiency syndrome.

    Annual review of immunology · January 1, 1985 · Review · cited 380 times

    PMID 2415141 · DOI 10.1146/annurev.iy.03.040185.002401 · Reviews and meta-analyses

  2. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide.

    Proceedings of the National Academy of Sciences of the United States of America · February 1, 1977 · Animal study · cited 355 times · open access

    PMID 265536 · DOI 10.1073/pnas.74.2.725 · Animal studies

  3. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report.

    Medicine · July 1, 2020 · Case report · cited 327 times · open access

    PMID 32756149 · DOI 10.1097/md.0000000000021429 · Human clinical research

  4. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus.

    The Journal of biological chemistry · February 1, 1979 · Animal study · cited 265 times · open access

    PMID 216684 · DOI 10.1016/s0021-9258(17)37900-0 · Animal studies

  5. Thymosin stimulates secretion of luteinizing hormone-releasing factor.

    Science (New York, N.Y.) · November 1, 1981 · Animal study · cited 253 times

    PMID 7027442 · DOI 10.1126/science.7027442 · Animal studies

Latest publications

  1. A novel porcine interleukin-2-interferon-α-thymosin α1 tripartite fusion protein confers antiviral activity against pseudorabies virus.

    Veterinary microbiology · October 8, 2026 · Animal study · cited 0 times

    PMID 42858589 · DOI 10.1016/j.vetmic.2026.111247 · Animal studies

  2. Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.

    Pharmaceuticals (Basel, Switzerland) · September 19, 2026 · Review · cited 0 times · open access

    PMID 42797537 · DOI 10.3390/ph19091492 · Reviews and meta-analyses

  3. Efficacy and safety of thymosin α1 combined with chemotherapy for gastric cancer: a systematic review and meta-analysis of randomized controlled trials.

    Frontiers in immunology · September 18, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42827862 · DOI 10.3389/fimmu.2026.1884797 · Reviews and meta-analyses

  4. Thymosin-ɑ1 for people with chronic hepatitis B.

    The Cochrane database of systematic reviews · September 9, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42713852 · DOI 10.1002/14651858.cd014610.pub2 · Reviews and meta-analyses

  5. Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany) · September 3, 2026 · Animal study · cited 0 times · open access

    PMID 42693587 · DOI 10.1002/advs.202522372 · Animal studies

  6. Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.

    Cancer research · September 1, 2026 · Animal study · cited 0 times

    PMID 42295795 · DOI 10.1158/0008-5472.can-25-5547 · Animal studies

  7. Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives.

    European journal of pharmacology · August 26, 2026 · Review · cited 0 times

    PMID 42641753 · DOI 10.1016/j.ejphar.2026.179277 · Reviews and meta-analyses

  8. Association between thymosin α1 therapy and 28-day mortality risk in critically ill patients with tuberculosis-related sepsis: a retrospective cohort study.

    BMC infectious diseases · August 5, 2026 · Observational human study · cited 0 times · open access

    PMID 42972235 · DOI 10.1186/s12879-026-14132-6 · Human clinical research

  9. Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro.

    Asian Pacific journal of cancer prevention : APJCP · June 1, 2026 · In vitro study · cited 0 times · open access

    PMID 42345155 · DOI 10.31557/apjcp.2026.27.6.2089 · In vitro studies

  10. Regarding IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.

    Journal of gastroenterology and hepatology · May 29, 2026 · Editorial, letter or other · cited 0 times

    PMID 42212632 · DOI 10.1111/jgh.70471 · Commentary and other

Browse all 782 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Tα1; Thymalfasin; Thymosin Alpha-1; Thymosine Alpha 1; Zadaxin

((TITLE_ABS:"Tα1" OR CHEM:"Tα1" OR TITLE_ABS:"Talpha1" OR CHEM:"Talpha1" OR TITLE_ABS:"Talpha 1" OR CHEM:"Talpha 1") OR (TITLE_ABS:"Thymalfasin" OR CHEM:"Thymalfasin") OR (TITLE_ABS:"Thymosin Alpha-1" OR CHEM:"Thymosin Alpha-1" OR TITLE_ABS:"Thymosin Alpha1" OR CHEM:"Thymosin Alpha1") OR (TITLE_ABS:"Thymosine Alpha 1" OR CHEM:"Thymosine Alpha 1" OR TITLE_ABS:"Thymosine Alpha1" OR CHEM:"Thymosine Alpha1") OR (TITLE_ABS:"Zadaxin" OR CHEM:"Zadaxin")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Thymosin Alpha-1 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/thymosin-alpha-1